cyrilzakka/clinical-trials huggingface dataset:
Non Surgical Periodontal Treatment Effect on Il-17 and Il-18 in Aggressive Periodontitis

clinical parameters and IL-17 and Il-18 GCF levels were measured in 25 aggressive periodontitis patients compared to 25 periodontally healthy individuals.

It was observed that that Clinical parameters and Il-17 and Il-18 levels are higher before treatment but decreased after treatment which suggests role of these interleukins in pathogenesis of aggressive periodontitis .

Aggressive periodontitis is a type of rapidly progressing periodontal diseases .The three classic primary characteristics of this disease are ; occurring in young healthy patients with rapid attachment loss and familial aggregation .Bacteria-host interactions, insufficiencies in host defenses and possibly a genetic predisposition represent the etiologic factors . Beside the young age of onset, important factors as involvement of host factors and non-plaque-related etiologic factors have also been proposed .

Aim of the study:

Objectives were to compare and correlate the clinical parameters and biochemical parameters (Il-17 and Il-18 levels in GCF) of aggressive periodontitis patients (At baseline and after three months of nonsurgical treatment) versus periodontally healthy subjects at baseline.

Subjects and methods:

Populations included in the study:

A total of fifty individuals were enrolled and categorized as; group A that included twenty five aggressive periodontitis patients and group B which included twenty five periodontally healthy controls.

Clinical parameters:

Plaque index (PI) ,gingival index (GI), Probing pocket depth (PPD) and clinical attachment level (CAL) were measured at baseline for both groups and after three months of non surgical periodontal treatment completion for group A.

GCF sampling:

In group A ,the site with deepest probing depth was selected for GCF sampling while for group B , any site was sampled using PerioPaper strips .

Phase I periodontal treatment After baseline GCF sample collection and clinical measurement recordings, group A patients received phase I periodontal treatment.

Analysis of Il-17 and Il-18 levels in GCF:

GCF samples were examined by enzyme-linked immunosorbent assay (ELISA).Procedures were performed according to the directions in the kits.

Eligibility Criteria:
Inclusion Criteria:

-Medically free subjects.

Exclusion Criteria:

* Subjects with periodontal surgeries in the last 6 months.
* Subjects with prior use of antibiotics in the last 6 months.
* Smokers.
* Pregnant females.
* Lactating females.
Snooze Control: Sleep Duration & Glucose Metabolism

This project investigated how glucose metabolism differs due to sleep deprivation for three consecutive nights as compared to sufficient sleep for three nights by examining concentrations of glucose, insulin, and other factors involved in glucose metabolism.

16 participants were enrolled in the study (8 females, 8 males) aged 18-25 years. In order for the participants to qualify for the study, each had to wear a pedometer for a week before the study began to determine eligibility. Each participant came to the lab for an oral glucose tolerance test on a morning, following three nights when they were sleep deprived, and on another morning when they had three nights' sufficient sleep. The sequence of the oral glucose tolerance tests were randomly assigned. The sleep duration for participants was monitored by the readings of the sleep monitors that each participant wore. The oral glucose tolerance tests were performed after an overnight fast. A 20-gauge polyethylene catheter was placed in the antecubital vein for blood sampling. Blood samples were drawn once (0 min) before and 4 times (30, 60, 90, and 120 min) after a 75g glucose drink was consumed for the determination of plasma glucose, insulin, and concentrations of other factors. Each participant was told to continue their regular routine during the study period, including diet, caffeine usage, and exercise.

Eligibility Criteria:
Inclusion Criteria:

* healthy college-aged males and females
* being minimally active

Exclusion Criteria:

* average more than 15,000 steps a day
* major health issues such as heart disease, diabetes
* taking medication to help with sleep or using a sleeping device
* any type of sleep problem such as sleep apnea
A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity

This study forms part of an integrated, multi-study effort to identify potential biomarkers of reactogenicity to vaccines. We have selected PET-CT as it is in routine clinical use and has been serendipitously shown to image lymph nodes and injection site inflammation after immunisation.The study's objectives are exploratory:

1. To methodically characterise relative anatomical distribution and intensity of post-immunisation innate immune activation visualised by PET-CT after immunisation with adjuvanted and non-adjuvanted vaccines.
2. To correlate PET/CT changes with diary card recorded symptoms of reactogenicity.


Eligibility Criteria:
Inclusion Criteria:

1. Able to read and understand the informed consent form (ICF), and understand study procedures
2. Signed the ICF
3. Healthy male aged 18'Äì55 years inclusive
4. BMI 19'Äì27 kg/m2
5. Pre-immunised with hepatitis B vaccine on the basis of immunisation history if Fendrix or Engerix B is to be the study vaccine
6. Available for follow-up for the duration of the study
7. Is, in the opinion of the investigator, healthy on the basis of a medical history, symptom directed medical examination and vital signs
8. Have not undergone research radiation exposures, and agree to avoid such exposures, for 12 months before/after this study
9. Be willing to avoid vigorous exercise or contact sports between vaccination and PET scan (e.g. gym workouts, prolonged cycling, rowing, martial arts or rugby)

Exclusion Criteria:

1. History of hypersensitivity to any of the vaccine components or a history of any allergy that in the opinion of the investigator would contraindicate participant participation
2. Use of steroids or immunosuppressive/immunomodulating drugs either orally or parenterally within 3 months of the PET scan. (Topical/ocular/nasal/inhaled steroids are allowed.)
3. Expression of only TSPO with low-affinity to PBR28, on the basis of TSPO genotype
4. Currently participating in a clinical study with a drug or device
5. Any condition that, in the investigator'Äôs opinion, compromises the participant'Äôs ability to meet protocol requirements or to complete the study
6. Unable to read and speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent
Dexamethasone for IPACK Block with ACB in Total Knee Arthroplasty

Effect of adding Dexamethasone to Infiltration between the Popliteal Artery and Capsule of the Knee Block with ACB in Patients undergoing Total Knee Arthroplasty

Knee arthroplasty is one of the most common orthopaedic procedures, especially in elderly patients, due to the deformation of joints. Patients may complain of severe pain due to surgical trauma and prostheses. Regional anaesthesia methods may be performed to reduce the inflammatory response, opioid consumption, and opioid-related side effects.

Eligibility Criteria:
Inclusion Criteria:

* patients scheduled for total hip arthroplasty
* patients aged \>65 and \<100 years
* patients able to provide informed consent
* patients able to reliably report symptoms to the research team

Exclusion Criteria:

* inability to provide first-party consent due to cognitive impairment or a language barrier
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging

The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance

After being informed about the study and potential risks, all patient giving wirtting informed consent.

During surgery, tissue and blood samples will be conserved for the study. In this study will be compared images obtained in vivo before surgical management, ex vivo images obtained on excised tissues during surgery, histological data obtained during surgery.

Eligibility Criteria:
Inclusion Criteria:

* Patient aged \>18
* Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment
* Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures,
* Patient who has given informed, written and express consent,
* Patient affiliated with a French health insurance scheme.

Exclusion Criteria:

* Early-stage disease (FIGO \<IIIB) or presence of extraperitoneal metastases,
* Patient who will not have surgery
* Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
* Patient under guardianship, curatorship or safeguarding of justice,
* Pregnant and/or nursing patient,
* Patient with a history of other cancers within 5 years/10 years prior to inclusion
Real-world Evaluation of Qingxin Zishen Decoction on Ovarian Reserve Function Clinical Efficacy in Patients With Decreased

A prospective cohort study evaluated the clinical efficacy of Qingxin Zishen Decoction


Eligibility Criteria:
1.AMH AMH \<1.1ng/ml 2.AFC: AFC \<5\~7 ovaries on both sides 3.Basic FSH: Basal FSH for two consecutive menstrual cycles ≥10 IU/L 4.Aged between 25 and 45 years old, female.

1. Those with reduced ovarian function caused by ovarian or uterine surgery, radiotherapy and chemotherapy;
2. Liver function (AST or ALT) and renal function (BUN or Ccr) are greater than 2 times the normal value;
3. Patients with a history of mental illness or legal disability
4. Those who have used endocrine-affecting drugs within 3 months before the study, estrogen, progesterone or related compound preparations, oral contraceptive pills, Chinese medicines or Chinese patent medicines related to the treatment of premature ovarian failure. Our hospital's preparations include Wu Turtle Rejuvenation Oral Liquid and Kuntai Capsules.
5. Patients with unexplained irregular vaginal bleeding
6. Patients who are participating in clinical trials of other drugs
7. For women who want to have children, those whose spouse's semen test fails to meet the standard will be excluded.
Pharmacokinetic Study of Vancomycin, Clindamycin And/or Gentamicin Administration During Surgery Using a Microdialysis Procedure

The surgical site infection is one of the most important causes of postoperative morbidity. The appropriate antibiotic prophylaxis is one of the most effective way to prevent surgical site infections. The beta-lactam are the most frequent antibiotics recommended for surgical prophylaxis and patients known to be allergic to beta-lactam are more likely to presented surgical site infection, probably due to use of others antibiotic such as vancomycin or clindamycin.

The main objective of the study is to describe the tissu and plasma pharmacokinetics of vancomycin, clindamycin and gentamicin using as surgical antibiotic prophylaxis in patients with beta-lactam hypersensivity and to predict the probability of target attainment for usual bacteria.


Eligibility Criteria:
Inclusion Criteria:

* Adult patient between 18 and 80 years old
* Patient with history of beta-lactam hypersensitivity
* Patient who underwent abdominal or orthopedic surgery whose forseeable time exceeds 1 hour and requires a surgical antibiotic prophylaxis by vancomycin or clindamycin + gentamicin

Exclusion Criteria:

* morbid obesity (BMI \> 35 kg/m2)
* mild to severe renal impairment (clearance creatinine \< 60 ml/min)
* vancomycin, clindamycin or gentamicin hypersensitivity
* pregnancy
Intestinal Colonization in Newborn Infants With Enterostomy

The human microbiota, a collection of microorganisms mostly settled in the gastrointestinal tract, plays a major role in the maintenance of the hosts' health and in development of disease as well. Exposure to different conditions early in life contributes to distinct "pioneer" bacterial communities, which shape the newborn infants' development and influence their later physiological, immunological and neurological homeostasis. Newborn infants with congenital malformations of the gastrointestinal tract (CMGIT), necrotizing enterocolitis (NEC), and spontaneous intestinal perforation (SIP) commonly require abdominal surgery and enterostomy. While intestinal microbiota has been extensively studied in infants with anatomically uninterrupted intestine, the knowledge of longitudinal intestinal colonization in this population is scarce.

This is an exploratory, observational, and longitudinal prospective study, primarily aimed to determine longitudinally the colonization of the proximal remnant intestine, in newborn infants with enterostomy after surgery (three weeks) for CMGIT, NEC and SIP. The secondary aim is to explore the associations of the colonization with the mode of delivery, gestational age, postnatal age, duration of fasting, type of enteric feeding, antimicrobial therapy, H2-receptor antagonist therapy, and length of proximal remnant intestine.


Eligibility Criteria:
Inclusion criteria: newborn infants with enterostomy after surgery for CMGIT, NEC or SIP, consecutively admitted

Exclusion criteria: newborn infants with diagnosed inborn errors of metabolism, those whose parents or legal guardians will not consent to participate or withdrawn the consent, and those who had not complete 21 days of follow-up.
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly

OBJECTIVES: I. Determine whether release of endogenous growth hormone (GH)-releasing hormone is involved in GH responses to clonidine, pyridostigmine, levodopa, arginine, GH-releasing peptide, insulin-induced hypoglycemia, and exercise in patients with acromegaly.

II. Determine whether endogenous GH-releasing hormone influences the maintenance of GH hypersecretion.

PROTOCOL OUTLINE: Growth hormone-releasing hormone antagonist (GHRH-A) is administered to volunteers and followed with 1 of these challenges: insulin, clonidine, pyridostigmine, arginine, levodopa, growth hormone-releasing peptide, or exercise. Tests are repeated with normal saline as the control; the order of administration (control vs. pharmacologic stimulation) is randomly assigned.

Patients receive GHRH-A (dose determined in volunteer study), thyrotropin-releasing hormone, and growth-releasing hormone.

All stimulation tests follow an overnight fast.

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Active acromegaly with growth hormone (GH) hypersecretion confirmed within 1 month prior to entry, i.e.: Somatomedin C elevated GH not below 2 ng/mL on standard 100 g oral glucose tolerance test Postmenopausal and hypogonadal women eligible Volunteers aged 18 to 30 recruited for up to 3 stimulation tests Weight within 15% of ideal Physical exam normal No history of disease No requirement for medication No medical or mental contraindication to protocol participation, including heavy alcohol or tobacco use No pregnant women --Prior/Concurrent Therapy-- Not specified --Patient Characteristics-- Age: 18 to 65 Hematopoietic: No anemia Hepatic: No hepatic disease Renal: No renal disease Cardiovascular: No uncontrolled hypertension No heart disease Other: No requirement for replacement gonadal steroids, glucocorticoids, or thyroxine No mental illness No heavy alcohol use No tobacco use No drug abuse No medical contraindication to protocol therapy
Evaluate Serious Illness Treatment Preferences and Outcomes in the Patients Receiving Peritoneal Dialysis

The goal of this clinical research study is to study the cardiopulmonary resuscitation (CPR) preferences of patients receiving peritoneal dialysis and how these preferences are associated with their responses to questions about aspects of end-of-life care.

This prospective cohort clinical trial aims to provide evidence on the preferences of end of life care in patients receiving peritoneal dialysis, thereby provide optimal care according to patients' preferences and choices through effective communication and clear goals of care.

This is a prospective cohort study to survey cardiopulmonary resuscitation (CPR) preferences of patients receiving peritoneal dialysis and how these preferences are associated with their responses to questions about aspects of end-of-life care for end stage renal disease(ESRD) patients, and actively survey their palliative care need to share decision making with ESRD patient whether to receive standardized palliative care interventions by the interdisciplinary palliative care team, including treatment of suffering symptoms, non-pharmacologic therapies. The investigators will enroll 500 patients. The eligibility criteria are shown later part. After obtaining consent from the patient, the investigators will conduct baseline assessments and start the patient on a 10minutes questionnaire. The questionnaire was cited from 2016-CA-POLST, which is in Chinese version for better understanding. POLST is an approach to end-of-life planning based on conversations between patients, loved ones, and health care professionals designed to ensure the patient only receive the care that patients themselves wish to. After that, the investigators will active survey the patient who had higher mortality rate within one year by using 1. Palliative Care Screening Tool (PCST)， 2."Surprise" Question，3. Integrated model risk≥10%. For the patient who had higher mortality rate within one year (\>10%), the investigators would evaluate the degree of symptoms burden by using ESAS-r: Renal. For the patient who had moderate to severe symptoms burden, the investigators would share decision making with them to discuss whether to receive combined palliative care. The investigators would divide the patients to two group according to patient decision. (1) Usual ESRD care team (2) Usual ESRD care + combined palliative care team. And the investigators would compare the quality of life and quality of death, and symptoms burden after 3/6/12 months receiving timely integrated palliative care to the other group Evaluate outcomes including quality of life (EQ-5D-5L), quality of death (GDS), symptoms burden(ESAS-r:Renal)

Eligibility Criteria:
Inclusion Criteria:

1. \[Patients\] Diagnosis of ESRD
2. \[Patients\] Under treatment of peritoneal dialysis
3. \[Patients\] Age 20 years or older
4. \[Caregivers\] Age20 years or older

Exclusion Criteria:

* \[Patients\] unable to understand or fill in the questionnaire
Drivers of Eosinophilic COPD Exacerbations

Main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic COPD exacerbations and other subtypes.

Main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic COPD exacerbations and other subtypes to better understand why some patients are more at risk for eosinophilic COPD exacerbations. Secondary objectives:

1. Investigate differences in microbiome composition and immunophenotyping profiles in peripheral blood per subtype.
2. Assess for clinical differences between all COPD exacerbation subtypes.
3. Assess if and how baseline meta-transcriptomics either in nasal epithelium or sputum and blood immunophenotyping can be utilized to predict COPD exacerbation subtype.
4. Determine if the microbiome in sputum and nasal epithelial material are comparable.
5. Determine if different subtypes of COPD exacerbations respond differently to standard treatment with oral prednisolone (40 mg daily) with or without antibiotics.
6. To evaluate if metabolic responses during recovery are different in patients with increased systemic inflammation compared to patients without systemic inflammation at exacerbation

Eligibility Criteria:
Inclusion Criteria:

1. COPD patient admitted to the hospital for an acute exacerbation of COPD
2. Physician diagnosed COPD according to the GOLD 2020 guidelines, including symptoms consistent with COPD, post-bronchodilator FEV1 \< 80% predicted and FEV1/FVC \< 70%.
3. Age \> 40 years.
4. Smoker or ex-smoker, ≥ 10 pack years of smoking.

Exclusion Criteria:

1. Current asthma, or prior physician diagnosis of asthma without a symptom- free interval of at least 10 years before the age of 40.
2. Chronic use of prednisolone.
3. Use of systemic corticosteroids ≥4 days prior to hospital admission.
4. Necessity (upon hospitalization) for non-invasive ventilation or ICU admission.
5. Pneumonia at presentation documented by chest roentgenography.
6. Any other clinically relevant lung disease deemed to interfere with the concept of the study design.
7. Allergy to systemic corticosteroids or to antibiotics.
8. Females of childbearing potential without an efficient contraception unless they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH \>40 mIU/mL or the use of one or more of the following acceptable methods of contraception:

   1. Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy).
   2. Hormonal contraception (implantable, patch, oral, injectable).
   3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/cream/suppository.
   4. Continuous abstinence
9. Pregnancy or lactation.
10. Known immunodeficiency.
11. Life expectancy less than 60 days
A Single-Group Study to Evaluate the Effects of an Eyelash Serum on Improving Eyelash Growth

This study will evaluate the efficacy of the DIME Beauty Eyelash Boost Serum in improving the growth of the eyelashes and their appearance in terms of length, fullness, and thickness. This study will last for 60 days. The study will be conducted as a single-arm trial in which all participants will use the test product. Participants will be required to undertake questionnaires at Baseline, Day 30, and Day 60, photos will be taken at Baseline, Day 30, and Day 60, and expert eyelash grading will take place at Baseline and Day 60.


Eligibility Criteria:
Inclusion Criteria:

Females aged 18-65. Wish to improve their eyelash growth. Wish to improve their eyelash length, thickness, and fullness. Have a smartphone or camera to take before-and-after selfies.

Exclusion Criteria:

Anyone not in good health. Anyone who has any chronic health conditions such as oncological or psychiatric disorders.

Anyone who has undergone any procedures that target the eyelashes in the past 3 months, or is planning to in the next 60 days. This includes eyelash lifts, tints, and extensions.

Anyone who has recently started using any product or taking any supplements that target eyelash growth, or who is planning to in the next 60 days.

Anyone who has any known serious allergic reactions that require the use of an Epi-Pen.

Anyone who is pregnant, breastfeeding, or wanting to become pregnant over the next three months.

Anyone who cannot/will not commit to the study protocol. Anyone with a history of substance abuse.